| Literature DB >> 32275896 |
Armin Rashidi1, Daniel J Weisdorf2.
Abstract
Despite advances in antimicrobial treatments, infection remains a common complication of intensive chemotherapy in patients with acute leukemia. It has become progressively apparent that the current antimicrobial focus has shortcomings that result from disruption of the commensal microbial communities of the gut. These effects, collectively known as dysbiosis, have been increasingly associated worldwide with growing complications such as Clostridioides difficile infection, systemic infections, and antibiotic resistance. A revision of the current practice is overdue. Several innovative concepts have been proposed and tested in animal models and humans, with the overarching goal of preventing damage to the microbiota and facilitating its recovery. In this review, we discuss these approaches, examine critical knowledge gaps, and explore how they may be filled in future research.Entities:
Keywords: Acute leukemia; Chemotherapy; Dysbiosis; Microbiota; Transplantation
Mesh:
Substances:
Year: 2020 PMID: 32275896 PMCID: PMC7605891 DOI: 10.1016/j.trsl.2020.03.011
Source DB: PubMed Journal: Transl Res ISSN: 1878-1810 Impact factor: 7.012